Breast Cancer Clinical Trial 20213070

[LCID Study Number: 20213070]

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cance

The purpose of this study is to evaluate the efficacy and safety of giredestrant compared with endocrine therapy of physician’s choice (TPC) in participants with ER+ HER2- early breast cancer (EBC) who have completed neoadjuvant chemotherapy and have had surgery.

Disease/Condition: Breast Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

Protocol #: 20213070
Principal Investigator(s): Corrine Zarwan
Trial Phase: Sponsor Initiated Study Phase 3